Aarti Drugs
AARTIDRUGS
Aarti Drugs Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 1,230 |
| Weekly | 1.88% | 2,37,238 |
| Monthly | 4.74% | 29,18,945 |
Aarti Drugs Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| AARTIDRUGS | - | 1.88% | 4.74% |
| Index | - | - | - |
| Peer Avg. | -0.04% | 5.38% | 11.47% |
Aarti Drugs Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| AARTIDRUGS | 19.87 | 3.96 | 14.41 | 21.16 | 20.78 | 0.22 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Aarti Drugs Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 16.53% | -25.61% | 21.16% | 20.78% |
| FY '20-21 | 18.22% | 94.13% | 35.30% | 33.94% |
| FY '19-20 | 14.06% | 56.52% | 23.72% | 21.34% |
Aarti Drugs Shareholding Pattern
Aarti Drugs Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 2,369.91 | 2,043.03 | 334.93 | 200 |
| FY '20-21 | 2,034.84 | 1,612.46 | 427.85 | 269.06 |
| FY '19-20 | 1,720.51 | 1,463.77 | 258 | 138.54 |
Aarti Drugs Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| AARTIDRUGS | 2,369.91 | 2,043.03 | 334.93 | 200 |
| INDOCO | 1,540.23 | 1,214.16 | 332.78 | 154.66 |
| FDC | 1,523.44 | 1,273.18 | 327.68 | 217.90 |
Aarti Drugs Share Price
Aarti Drugs Limited is an Indian pharmaceutical company that manufactures active ingredients (APIs), pharmaceutical intermediates and specialty chemicals. The company focuses on manufacturing products through its wholly owned subsidiary Pinnacle Life Science Private Limited. The company's API products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin. Its pharmaceutical intermediates include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemicals such as benzenesulfonyl chloride and methyl nicotinate. The company's products under development include the treatment of alcoholism, anticoagulants, hyperphosphatemia, cholesterol, cardiovascular diseases, cardioprotective agents and diabetes drugs.